These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 6953613

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Favourable effect of combined Miscleron-Xavin treatment on HDL-cholesterol level.
    Pados G, Kusztos D, Németh-Csóka M, Valyon M, Farkas K.
    Ther Hung; 1983; 31(2):59-61. PubMed ID: 6571183
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [Abstract] [Full Text] [Related]

  • 9. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
    Słowińska R, Bochenek W, Unlot J.
    Pol Tyg Lek; 1983 Apr 25; 38(17):529-32. PubMed ID: 6356087
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Pharmacology and mechanism of action of etofibrate].
    Schatton W.
    Med Welt; 1982 Sep 24; 33(38):1310-4. PubMed ID: 6752630
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Effect of diet and drug therapy on the level of high density lipoprotein cholesterol in patients with primary hyperlipoproteinemia].
    Padosh D, Kustosh D, Puchok I, Dem'ianova N, Audikovski M.
    Klin Med (Mosk); 1981 Sep 24; 59(9):45-8. PubMed ID: 7311430
    [No Abstract] [Full Text] [Related]

  • 18. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C, Schwartzkopff W, Schilling A, Calder D, Scheffler W.
    Artery; 1980 Sep 24; 8(2):128-33. PubMed ID: 7458677
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
    Mordasini R, Riesen W, Oster P, Keller M, Middelhoff G, Lang PD.
    Atherosclerosis; 1981 Oct 24; 40(2):153-8. PubMed ID: 6796096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.